Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study
Authors Tong G, Li S, Lin L, He L, Wang L, Lv G, Zheng R, Wang S
Received 20 November 2019
Accepted for publication 2 March 2020
Published 8 April 2020 Volume 2020:12 Pages 2481—2489
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Antonella D'Anneo
Gangling Tong,1,* Shuluan Li,2,* Lin Lin,3,* Lirui He,1 Li Wang,1 Guoqing Lv,1 Ruinian Zheng,4 Shubin Wang1
1Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, People’s Republic of China; 2National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, People’s Republic of China; 3Department of Oncology, Shenzhen Second People’s Hospital, Shenzhen, Guangdong 518036, People’s Republic of China; 4Department of Oncology, Affiliated Dongguan People’s Hospital, Southern Medical University, Dongguan, Guangdong 523000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Ruinian Zheng
Department of Oncology, Affiliated Dongguan People’s Hospital, Southern Medical University, Wandao Road (South), Xinguyong Village, Wanjiang District, Dongguan, Guangdong 523000, People’s Republic of China
Department of Oncology, Peking University Shenzhen Hospital, Lianhua Road (North), Futian District, Shenzhen, Guangdong 518036, People’s Republic of China
Background: The aim of this study was to evaluate the efficacy and safety of trastuzumab, combined with the FLOT regimen, in the perioperative treatment of resectable HER-2-positive advanced gastric cancer.
Methods: Overall, 45 patients were divided into two groups; 29 patients in the experimental group were treated with trastuzumab combined with FLOT and 16 patients in the control group were treated with FLOT alone. The primary endpoint was objective response rate (ORR), and the secondary endpoints were disease control rate (DCR), tumor regression grade (TRG), surgical margin, side effects, and overall survival.
Results: In the experimental and control groups, ORR was 72.4% and 43.8% (p=0.226), DCR was 89.7% and 87.5%, R0 resection rate was 96.5% and 93.7%, total/subtotal tumor regression grade was 17.2% and 6.3%, partial tumor regression grade was 27.6% and 18.7% (p=0.468), and 2-year survival rate was 78.1% and 73.9% (p=0.932), respectively. The common side effects were agranulocytosis and vomiting. There was no significant difference between the two groups.
Conclusion: Trastuzumab combined with FLOT has a good curative effect and safety profile in the perioperative treatment of patients with resectable HER-2-positive advanced gastric cancer. In addition, trastuzumab + FLOT had the same result as FLOT alone, as there was no significant benefit with the addition of T in the group studied.
Keywords: gastric cancer, HER2, perioperative chemotherapy, trastuzumab
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]